Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy

Autor:	Junyi Shen, Weili Qi, Junlong Dai, Shusheng Leng, Kangyi Jiang, Yu Zhang, Shun Ran, Chuan Li, Tianfu Wen
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	Hepatitis B virus Carcinoma Hepatocellular Guanine Hepatocellular carcinoma Antiviral drugs Liver Neoplasms General Medicine Original Articles Antiviral Agents Hepatitis B Chronic Recurrence Hepatectomy Humans Tenofovir Retrospective Studies
Zdroj:	Chinese Medical Journal
ISSN:	2542-5641 0366-6999
Popis:	Background: Hepatectomy for hepatocellular carcinoma (HCC) beyond the Milan criteria is shown to be beneficial. However, a high rate of post-operative HCC recurrence hinders the long-term survival of the patients. This study aimed to investigate and compare the impacts of tenofovir (TDF) and entecavir (ETV) on the recurrence of hepatitis B viral (HBV)-related HCC beyond the Milan criteria. Methods: Data pertaining to 1532 patients who underwent hepatectomy and received antiviral therapy between January 2014 and January 2019 were collected from five centers. Recurrence-free survival (RFS) analysis was performed using the Kaplan–Meier method. Cox proportional hazards regression analysis was performed to determine prognostic factors for HCC recurrence. Results: The analysis incorporates 595 HBV-related HCC patients. The overall 5-year RFS was 21.3%. Among them, 533 and 62 patients received ETV and TDF treatment, respectively. The 1-, 3-, and 5-year RFS rates were 46.3%, 27.4%, and 19.6%, respectively, in the ETV group compared with 65.1%, 41.8%, and 37.2%, respectively, in the TDF group (P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25392ed42f3f07c9f8f4c0eddd705c35 http://europepmc.org/articles/PMC8812695 Zobrazit plný text záznamu